pith. sign in

arxiv: 1907.05934 · v1 · pith:ZYQAPM6Cnew · submitted 2019-07-12 · ⚛️ physics.med-ph

⁷Be and ²²Na radionuclides for a new therapy of cancer

V. I. Kukulin , A. V. Bibikov , E. V. Tkalya , M. Ceccarelli , I. V. Bodrenko This is my paper

Pith reviewed 2026-05-24 21:53 UTC · model grok-4.3

classification ⚛️ physics.med-ph
keywords neutron capture therapyberyllium-7sodium-22boron-10cancer radiotherapyradionuclidesgamma imaging
0
0 comments X

The pith

Beryllium-7 and sodium-22 absorb neutrons with cross sections about ten times larger than boron-10 and emit heavy charged particles.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper identifies beryllium-7 and sodium-22 as alternative nuclides for neutron-capture therapy of cancer. These have neutron absorption cross sections about ten times larger than the standard boron-10 and emit heavy charged particles. Such properties would permit lower concentrations of the therapeutic agent in tissues or reduced neutron fluxes during irradiation. In addition, the gamma rays emitted during their natural decay enable non-invasive imaging to track their distribution. These features could make neutron-capture therapy more practical.

Core claim

The radionuclides beryllium-7 and sodium-22 have neutron absorption cross sections approximately ten times greater than boron-10 and emit heavy charged particles upon neutron capture. This enables the use of lower nuclide concentrations in target tissues or reduced neutron irradiation fluxes. Detection of characteristic gamma radiation from their spontaneous decay allows for imaging and control of their accumulation in tissues.

What carries the argument

Neutron absorption cross sections of beryllium-7 and sodium-22 that are roughly ten times larger than boron-10, combined with emission of heavy charged particles and spontaneous gamma decay.

If this is right

  • Lower nuclide concentration can be used in target tissues.
  • Lower neutron irradiation flux can be applied.
  • Accumulation can be imaged and controlled by detecting gamma radiation from spontaneous decay.
  • Neutron-capture therapy could become safer, more efficient, and more widely used.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • The imaging capability could support real-time monitoring of agent uptake during treatment sessions.
  • These nuclides might allow neutron-capture therapy to be applied at lower overall radiation exposures to patients.
  • Production methods and biological compatibility of beryllium-7 and sodium-22 would need separate validation for clinical translation.

Load-bearing premise

The larger neutron absorption cross sections and heavy-particle emission of beryllium-7 and sodium-22 will translate into practical clinical advantages without introducing new biological or delivery complications beyond those of boron-10.

What would settle it

A measurement or trial showing that the neutron flux or nuclide concentration needed for equivalent tumor control with beryllium-7 or sodium-22 is not lower than with boron-10, or that gamma imaging does not improve treatment control.

Figures

Figures reproduced from arXiv: 1907.05934 by A. V. Bibikov, E. V. Tkalya, I. V. Bodrenko, M. Ceccarelli, V. I. Kukulin.

Figure 1
Figure 1. Figure 1: Schematic diagrams of the 7Be (a) and of the 22Na (b) spontaneous decay, the data are from [20] and [21], respectively. As the decay rate depends on the electronic density at the nucleus, 7Be has been used in the studies of the effect of the chemical environment onto the nuclear processes [22–24]. Besides, and even more importantly, 7Be is assumed to play a key role in the lithium yield of the big bang nuc… view at source ↗
read the original abstract

The $^{10}$B isotope has been almost exclusively used in the neutron-capture radiation therapy (NCT) of cancer for decades. We have identified two other nuclides suitable for the radiotherapy, which have ca.10 times larger cross section of absorption for neutrons and emit heavy charged particles. This would provide several key advantages for potential NCT, such as the possibility to use either a lower nuclide concentration in the target tissues, or a lower neutron irradiation flux. By detecting the characteristic $\gamma$ radiation from the spontaneous decay of the radionuclides, one can image and control their accumulation. These advantages could be critical for the revival of the NCT as a safer, more efficient and more widely used cancer therapy.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

2 major / 1 minor

Summary. The paper claims that the radionuclides ^7Be and ^22Na are suitable alternatives to ^10B for neutron-capture therapy (NCT) of cancer. They are asserted to have ca. 10 times larger neutron absorption cross sections and to emit heavy charged particles, which would allow lower nuclide concentrations in target tissues or lower neutron irradiation fluxes. Additionally, their spontaneous decay gammas can be used for imaging and controlling accumulation, potentially making NCT safer and more efficient.

Significance. Should the nuclear data claims be substantiated and the clinical translation challenges addressed, this proposal could significantly advance NCT by improving the therapeutic ratio and enabling better treatment verification. The suggestion of these specific nuclides for NCT is novel and, if validated, might contribute to reviving interest in the modality.

major comments (2)
  1. [Abstract] The central claim that ^7Be and ^22Na have 'ca.10 times larger cross section of absorption for neutrons' is presented without any supporting data, numerical values, references to nuclear databases (e.g., ENDF), or calculations. This is load-bearing for the asserted advantages of lower concentration or flux.
  2. [Abstract] There is no discussion of potential drawbacks from the radionuclides' intrinsic radioactivity, such as the 478 keV gamma from ^7Be electron capture or the 511 keV and 1.275 MeV emissions from ^22Na beta-plus decay, which could affect normal tissue dose and must be evaluated for net benefit.
minor comments (1)
  1. [Abstract] The abbreviation 'ca.' for 'circa' should be followed by a space before the number for standard formatting.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for the constructive comments and positive assessment of the proposal's novelty. We will revise the manuscript to address the points on the abstract by adding supporting nuclear data and a discussion of intrinsic radioactivity drawbacks.

read point-by-point responses

  1. Referee: [Abstract] The central claim that ^7Be and ^22Na have 'ca.10 times larger cross section of absorption for neutrons' is presented without any supporting data, numerical values, references to nuclear databases (e.g., ENDF), or calculations. This is load-bearing for the asserted advantages of lower concentration or flux.

    Authors: We agree that the abstract lacks explicit values and references. The thermal neutron capture cross sections are 3837 b for ^{10}B, 38400 b for ^{7}Be (~10x larger), and ~31100 b for ^{22}Na (from ENDF/B-VIII.0 and similar databases). We will insert these values with citations and a brief note on the resulting flux/concentration advantages into the revised abstract and main text. revision: yes

  2. Referee: [Abstract] There is no discussion of potential drawbacks from the radionuclides' intrinsic radioactivity, such as the 478 keV gamma from ^7Be electron capture or the 511 keV and 1.275 MeV emissions from ^22Na beta-plus decay, which could affect normal tissue dose and must be evaluated for net benefit.

    Authors: The referee is correct that drawbacks from intrinsic radioactivity are not discussed in the abstract. The manuscript focuses on imaging benefits from decay gammas but does not address additional dose. We will add a paragraph in the revised version noting the specific gamma energies and their potential contribution to normal tissue dose, while arguing that imaging-enabled control may offset this; however, a full net-benefit dosimetric analysis is beyond the scope of this proposal and would require separate Monte Carlo studies. revision: yes

Circularity Check

0 steps flagged

No circularity: proposal rests on external nuclear data, not self-referential derivation

full rationale

The manuscript advances a clinical suggestion by citing known neutron-capture cross sections and decay modes of ⁷Be and ²²Na. No equations, fitting procedures, ansatzes, or uniqueness theorems appear; the argument is an extrapolation from tabulated nuclear properties to possible therapeutic ratios. No load-bearing step reduces to a self-citation or to a fitted input renamed as a prediction. The central claim therefore remains independent of any internal derivation chain.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

The abstract introduces no free parameters, axioms, or invented entities; it relies on standard nuclear-physics concepts whose details are not provided.

pith-pipeline@v0.9.0 · 5670 in / 1173 out tokens · 34196 ms · 2026-05-24T21:53:25.613993+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

49 extracted references · 49 canonical work pages

  1. [1]

    D. E. Citrin, N. Engl. J. Med. 377, 1065 (2017)

    work page 2017

  2. [2]

    Baskar, K

    R. Baskar, K. A. Lee, R. Yeo, and K.-W. Yeoh, Int. J. Med. Sc i. 9, 193 (2012)

    work page 2012

  3. [3]

    De Ruysscher, G

    D. De Ruysscher, G. Niedermann, N. G. Burnet, S. Siva, A. W . M. Lee, and F. Hegi-Johnson, Nat. Rev. Dis. Prim. 5, 13 (2019)

    work page 2019

  4. [4]

    J. F. Ziegler, J. Biersack, and U. Littmark, The stopping and range of ions in solids (Perga- mon, New York, 1985)

    work page 1985

  5. [5]

    Mitin and A

    T. Mitin and A. L. Zietman, J. Clin. Oncol. 32, 2855 (2014)

    work page 2014

  6. [6]

    W. D. Newhauser and R. Zhang, Phys. Med. Biol. 60, R155 (2015)

    work page 2015

  7. [7]

    Terasawa, Ann

    T. Terasawa, Ann. Intern. Med. 151, 556 (2009)

    work page 2009

  8. [8]

    J. F. Williamson, Phys. Med. Biol. 51, R303 (2006)

    work page 2006

  9. [9]

    Jadvar, Am

    H. Jadvar, Am. J. Roentgenol. 209, 277 (2017)

    work page 2017

  10. [10]

    G. L. Locher, Am J Roentgenol 36, 1 (1936)

    work page 1936

  11. [11]

    L. Farr, W. Sweet, H. Locksley, and J. Robertson, Transa ctions of the American Neurological Association 13, 110 (1954)

    work page 1954

  12. [12]

    R. F. Barth, J. A. Coderre, M. G. H. Vicente, and T. E. Blue , Clin. Cancer Res. 11, 3987 (2005)

    work page 2005

  13. [13]

    R. F. Barth, M. H Vicente, O. K. Harling, W. Kiger, K. J. Ri ley, P. J. Binns, F. M. Wagner, M. Suzuki, T. Aihara, I. Kato, and S. Kawabata, Radiat. Oncol . 7, 146 (2012). 13

    work page 2012

  14. [14]

    L. J. Slatkin DN, Javid MJ, Joel DD, Kalef-Ezra JA, Ma R, F einendegen LE, J. Neurol. Neurobiol. 3 (2017), 10.16966/2379-7150.142

    work page doi:10.16966/2379-7150.142 2017

  15. [15]

    R. F. Barth, P. Mi, and W. Yang, Cancer Commun. 38, 35 (2018)

    work page 2018

  16. [16]

    R. L. Moss, Appl. Radiat. Isot. 88, 2 (2014)

    work page 2014

  17. [17]

    Cerullo, D

    N. Cerullo, D. Bufalino, and G. Daquino, Appl. Radiat. I sot. 67, 157 (2009)

    work page 2009

  18. [18]

    S. A. Enger, V. Giusti, M.-A. Fortin, H. Lundqvist, and P . M. af Rosensch¨ old, Radiat. Meas. 59, 233 (2013)

    work page 2013

  19. [19]

    Deagostino, N

    A. Deagostino, N. Protti, D. Alberti, P. Boggio, S. Bort olussi, S. Altieri, and S. G. Crich, Future Med. Chem. 8, 899 (2016)

    work page 2016

  20. [20]

    Tilley, C

    D. Tilley, C. Cheves, J. Godwin, G. Hale, H. Hofmann, J. K elley, C. Sheu, and H. Weller, Nucl. Phys. A 708, 3 (2002)

    work page 2002

  21. [21]

    M. S. Basunia, Nucl. Data Sheets 151, 1 (2018)

    work page 2018

  22. [22]

    Segre, Phys

    E. Segre, Phys. Rev. 71, 274 (1947)

    work page 1947

  23. [23]

    Daudel, Revue Scientifique 85, 162 (1947)

    R. Daudel, Revue Scientifique 85, 162 (1947)

    work page 1947

  24. [24]

    E. V. Tkalya, A. V. Avdeenkov, A. V. Bibikov, I. V. Bodren ko, and A. V. Nikolaev, Phys. Rev. C 86, 014608 (2012)

    work page 2012

  25. [25]

    R. H. Cyburt, B. D. Fields, K. A. Olive, and T.-H. Yeh, Rev . Mod. Phys. 88, 015004 (2016)

    work page 2016

  26. [26]

    Damone, M

    L. Damone, M. Barbagallo, M. Mastromarco, A. Mengoni, L . Cosentino, E. Maugeri, S. Heinitz, D. Schumann, R. Dressler, F. K¨ appeler, N. Colon na, P. Finocchiaro, J. Andrze- jewski, J. Perkowski, A. Gawlik, O. Aberle, S. Altstadt, M. A yranov, L. Audouin, M. Ba- cak, J. Balibrea-Correa, J. Ballof, V. B´ ecares, F. Beˇ cv´ a , C. Beinrucker, G. Bellia, A. ...

    work page 2018

  27. [27]

    P. E. Koehler and H. A. O’Brien, Phys. Rev. C 38, 2019 (1988)

    work page 2019

  28. [28]

    Carlson, V

    A. Carlson, V. Pronyaev, R. Capote, G. Hale, Z.-P. Chen, I. Duran, F.-J. Hambsch, S. Ku- nieda, W. Mannhart, B. Marcinkevicius, R. Nelson, D. Neudec ker, G. Noguere, M. Paris, S. Simakov, P. Schillebeeckx, D. Smith, X. Tao, A. Trkov, A. W allner, and W. Wang, Nucl. Data Sheets 148, 143 (2018)

    work page 2018

  29. [29]

    Tomandl, J

    I. Tomandl, J. Vac ´ ık, U. K¨ oster, L. Viererbl, E. A. Maugeri, S. Heinitz, D. Schumann, M. Ayra- nov, J. Ballof, R. Catherall, K. Chrysalidis, T. Day Goodacr e, D. Fedorov, V. Fedosseev, K. Johnston, B. Marsh, S. Rothe, J. Schell, and C. Seiffert, Phy s. Rev. C 99, 3 (2019)

    work page 2019

  30. [30]

    P. E. Koehler, C. D. Bowman, F. J. Steinkruger, D. C. Mood y, G. M. Hale, J. W. Starner, S. A. Wender, R. C. Haight, P. W. Lisowski, and W. L. Talbert, P hys. Rev. C 37, 917 (1988)

    work page 1988

  31. [31]

    Stopping-power and range tables for electrons, protons, a nd helium ions,

    M. J. Berger, J. S. Coursey, M. A. Zucker, and J. Chang, “Stopping-power and range tables for electrons, protons, a nd helium ions,” (2017), nIST Standard Reference Database 124, available at https://dx. doi.org/10.18434/T4NC7P

    work page doi:10.18434/t4nc7p 2017

  32. [32]

    Northcliffe and R

    L. Northcliffe and R. Schilling, At. Data Nucl. Data Table s 7, 233 (1970)

    work page 1970

  33. [33]

    Materials and methods are available as supplementary materials

    “Materials and methods are available as supplementary materials.”

    work page

  34. [34]

    P. M. Busse, O. K. Harling, M. R. Palmer, W. S. Kiger, J. Ka plan, I. Kaplan, C. F. Chuang, J. Tim Goorley, K. J. Riley, T. H. Newton, G. A. Santa Cruz, X.- Q. Lu, and R. G. Zamenhof, J. Neurooncol. 62, 111 (2003)

    work page 2003

  35. [35]

    Kiyanagi, Ther

    Y. Kiyanagi, Ther. Radiol. Oncol. 2, 55 (2018)

    work page 2018

  36. [36]

    Anderson, C

    I. Anderson, C. Andreani, J. Carpenter, G. Festa, G. Gor ini, C.-K. Loong, and R. Senesi, Phys. Rep. 654, 1 (2016). 15

    work page 2016

  37. [37]

    J. A. Patton and T. G. Turkington, J. Nucl. Med. Technol. 36, 1 (2008)

    work page 2008

  38. [38]

    Hanaoka, T

    K. Hanaoka, T. Watabe, S. Naka, Y. Kanai, H. Ikeda, G. Hor itsugi, H. Kato, K. Isohashi, E. Shimosegawa, and J. Hatazawa, EJNMMI Res. 4, 70 (2014)

    work page 2014

  39. [39]

    Maugeri, S

    E. Maugeri, S. Heinitz, R. Dressler, M. Barbagallo, J. U lrich, D. Schumann, N. Colonna, U. K¨ oster, M. Ayranov, P. Vontobel, M. Mastromarco, J. Schell, J. M. Correia, and T. Stora, Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectro meters, Detect. Assoc. Equip. 889, 138 (2018)

    work page 2018

  40. [40]

    Bayanov, V

    B. Bayanov, V. Belov, E. Bender, M. Bokhovko, G. Dimov, V . Kononov, O. Kononov, N. Kuksanov, V. Palchikov, V. Pivovarov, R. Sal- imov, G. Silvestrov, A. Skrinsky, N. Soloviov, and S. Taskae v, Nucl. Instruments Methods Phys. Res. Sect. A Accel. Spectro meters, Detect. Assoc. Equip. 413, 397 (1998)

    work page 1998

  41. [41]

    Rubino, F

    C. Rubino, F. de Vathaire, M. E. Dottorini, P. Hall, C. Sc hvartz, J. E. Couette, M. G. Dondon, M. T. Abbas, C. Langlois, and M. Schlumberger, Br. J. Cancer 89, 1638 (2003)

    work page 2003

  42. [42]

    Toxicological profile for beryllium,

    “Toxicological profile for beryllium,” ATSDR report, a vailable at https://www.atsdr.cdc.gov/substances/index.asp

    work page

  43. [43]

    Tran, P.-J

    S. Tran, P.-J. DeGiovanni, B. Piel, and P. Rai, Clin. Tra nsl. Med. 6, 44 (2017)

    work page 2017

  44. [44]

    Bibikov, A

    A. Bibikov, A. Avdeenkov, I. Bodrenko, A. Nikolaev, and E. Tkalya, Phys. Rev. C - Nucl. Phys. 88 (2013), 10.1103/PhysRevC.88.034608

    work page doi:10.1103/physrevc.88.034608 2013

  45. [45]

    L. C. Perera, O. Raymond, W. Henderson, P. J. Brothers, a nd P. G. Plieger, Coord. Chem. Rev. 352, 264 (2017)

    work page 2017

  46. [46]

    K. J. Iversen, S. A. Couchman, D. J. Wilson, and J. L. Dutt on, Coord. Chem. Rev. 297-298, 40 (2015)

    work page 2015

  47. [47]

    Cell biology by the numbers,

    “Cell biology by the numbers,” Available at http://boo k.bionumbers.org/how-big-is-a- human-cell/

    work page

  48. [48]

    X-ray mass attenuation coefficients,

    “X-ray mass attenuation coefficients,” NIST database, a vailable at https://physics.nist.gov/PhysRefData/XrayMassCoef/tab4.html

    work page

  49. [49]

    L. M. Unger and D. Trubey, Specific gamma-ray dose constants for nuclides important to dosimetry and radiological assessment , Tech. Rep. (Oak Ridge National Lab., TN (USA), 1982). 16 SUPPLEMENT AR Y MA TERIALS Materials and Methods a. Typical cell size and mass. The average volumes of human cells range from 30 to 4 × 106 µm3, depending on the tissue [47];...

    work page 1982